Acute Myeloid Leukemia (AML)

After obtaining a BA/MS as a Vagelos Scholar in Molecular Life Sciences at the University of Pennsylvania in 2003, Dr. Lee received his MD from the University of Miami in 2007. Following his internal medicine residency at the University of Alabama at Birmingham, he completed his fellowship in hematology and oncology at the New York Presbyterian Hospital/Columbia University Medical Center from 2010-2013 where he focused on epigenetics of myelodysplastic syndromes (MDS) under Drs. Azra Raza and Benjamin Tycko. In July 2013, Dr. Lee was recruited to serve in the Leukemia Program in the Division

Dr. Lane received his MD and PhD degrees from Washington University. He completed his residency in internal medicine at Brigham and Women's Hospital, and his fellowships in hematology and medical oncology at DFCI. His research focuses on developing new treatments for leukemia by studying the genetic changes that occur in cancer and how they alter the normal development of blood cells.

Dr Kogan and GW Center for Integrative Medicine have been providing integrative and complementary consultations and services for patients with Bone Marrow Disorders.

Dr. Tapan Kadia received his M.D. degree from Robert Wood Johnson Medical School in Piscataway, New Jersey. He completed his clinical internship in 2002, clinical residency in 2004, and chief residency in 2005, each at Baylor College of Medicine... Dr. Kadia is an Associate Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas. He is actively involved in clinical and translational research for the treatment of patients with leukemia. His particular focus is in developmental therapeutics in acute leukemia, including individualized

Dr. Hanna is board certified in pediatrics and pediatric hematology-Oncology. He earned his medical degree from Aleppo University Faculty of Medicine in Aleppo, Syria. His post-graduate training in USA includes a pediatric residency at Duke University Medical Center in Durham, North Carolina, and a pediatric hematology-oncology fellowship at the Fred Hutchinson Cancer Research Center and Seattle Children’s Hospital in Seattle, Washington. Dr. Hanna is a member of several professional organizations, including the American Society of Pediatric Hematology Oncology, American Society of Hematology

Dr. Griffiths am board certified in hematology, oncology and internal medicine and hold medical licenses in New York and Maryland. She is a member of multiple professional organizations, including the American Society of Hematology, the American Association for Cancer Research, the Society for Immunotherapy of Cancer and the American Society of Oncology. Her research is focused on the mechanism of hypomethylating drugs (HMAs) in patients with myeloid cancer, specifically the contribution of the immune system to these responses. They have examined how HMAs can cause re-expression of proteins in